Paperpal Prime Logo

Therapeutic Advances in Hematology : Impact Factor & More

eISSN: 2040-6215pISSN: 2040-6207
JournalOpen Access

Key Metrics

CiteScore
0.7
H-Index
32
Impact Factor
< 5
SJR
Q2Hematology
SNIP
0.36
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Hematology

Therapeutic Advances in Hematology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time7
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2010
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 7
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Hematology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Hematology

Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Prognostic value of neutrophil-to-lymphocyte ratio among patients suffering from multiple myeloma: A systematic review and meta-analysis
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Clinical characteristics and outcome of CLL/SLL patients with renal involvement in the era of targeted drugs
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Low dose chidamide promotes inhibitory Fcγ receptorIIb expression on monocytes in ITP: A translational study of human ITP samples and ITP murine models
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Prognostic value of neutrophil-to-lymphocyte ratio among patients suffering from multiple myeloma: A systematic review and meta-analysis
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)
  • 1 Oct 2026
  • Therapeutic Advances in Hematology
Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone
  • 1 Oct 2026
  • Therapeutic Advances in Hematology

FAQs on Therapeutic Advances in Hematology